^
BIOMARKER:

PD-L2 overexpression

i
Other names: PDCD1LG2, Programmed Cell Death 1 Ligand 2, B7 Dendritic Cell Molecule, Programmed Death Ligand 2, Butyrophilin B7-DC, PDCD1 Ligand 2, PDCD1L2, B7-DC, CD273, PD-L2, B7DC, PDL2, PD-1-Ligand 2, CD273 Antigen, PD-1 Ligand 2, BA574F11.2, Btdc
Entrez ID:
Related biomarkers:
PD-L2 overexpression
Prostate Cancer
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L2 overexpression
Melanoma
nivolumab
Sensitive: C3 – Early Trials
PD-L2 overexpression
Melanoma
ipilimumab
Sensitive: C3 – Early Trials
PD-L2 overexpression
Melanoma
pembrolizumab
Sensitive: C3 – Early Trials
PD-L2 overexpression
SCCHN
pembrolizumab
Sensitive: C3 – Early Trials
PD-L2 overexpression
AML
avelumab
Resistant: D – Preclinical
PD-L2 overexpression
Colorectal Adenocarcinoma
PD-L1 inhibitor + PD-L2 inhibitor
Sensitive: D – Preclinical
PD-L2 overexpression
Endometrial Cancer
paclitaxel
Sensitive: D – Preclinical